October 19, 2012 / 11:52 AM / in 5 years

Novo Nordisk says EMA advisory panel recommends Tresiba

COPENHAGEN, Oct 19 (Reuters) - Denmark’s Novo Nordisk , the world’s biggest insulin producer, said on Friday the advisory panel to the European Medicines Agency (EMA) had recommended approving its long-acting insulin Tresiba.

The EMA’s final approval of a drug rarely goes against the view of the advisory panel.

The advisory panel of the United States Food and Drug Administration (FDA) is expected to publish its recommendation of a Tresiba approval on November 8.

Reporting by Mette Fraende; Editing by Helen Massy-Beresford

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below